[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Biopharma Credit Plc LSE:BPCR London Ordinary Share GB00BDGKMY29 ORD USD0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.004 0.41% 0.976 0.974 0.976 0.976 0.968 0.98 3,117,693 16:20:40
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Unknown 99.5 79.7 5.8 16.8 1,341

Biopharma Credit Share Discussion Threads

Showing 51 to 74 of 75 messages
Chat Pages: 3  2  1
DateSubjectAuthorDiscuss
15/9/2021
09:32
Liberum; Mkt Cap £970m | Share price $0.98 | Prem/(disc) -2.8% | Div yield 7.5% Event BioPharma Credit's NAV per share at 30 June 2021 was 99.8 cents (previously reported), representing a NAV total return of 3.2% over H1. We estimate look-through recurring EPS of 3.7 cents (1.05x dividend cover) and a capital loss of 0.4 cents. The portfolio generated additional liquidity totalling $124m, including pre-payments. This included $97m from payments from the Sebela loan, including a final prepayment premium totalling $1.5m. The final payment was made on 30 June 2021, with BPCR realising an IRR of 11.2% on the investment. During H1, BPCR and BioPharma-V2 agreed a $300m senior secured term loan with LumiraDx, a UK based diagnostics company. LumiraDx is now the second largest loan in the portfolio behind Sarepta ($350m). At the period-end, BPCR's cash balance was $211.3m, representing 15.5% of NAV. Post-period end corporate updates for the BPCR included: Proposed main market listing - an application has been submitted to trade on the premium segment of the LSE. Continuation resolution brought forward - this has been brought forward by a year from the required five year mark to 30 September 2021 and will be held at the forthcoming AGM. RCF refinanced - the committed RCF with JPMorgan Chase has been reduced from $200m to $50m, while allowing for an increase up to $200m. The margin payable under the RCF has reduced from 4.00% to 2.75%. View BPCR has continued to generate a high level of income, despite the impact of cash drag, with credit quality remained materially unaffected by the pandemic. We believe the current 2.8% discount and 7.5% dividend yield are an attractive entry point for a high quality portfolio that has delivered consistent returns since launching in 2017. The recent corporate announcements should positively support sentiment. Life sciences companies will require substantial capital over the coming years, as the number of number of products undergoing clinical trials continues to grow. The manager continues to report a strong pipeline and the focus will be on deploying resources. The loans are typically structured to provide protection against cash drag from repayments in the form of prepayment fees and make-whole penalties. BPCR's origination pipeline is likely to be further supported by the growing need for acquisition financing. Global life sciences M&A volume over H1 totalled $111bn, a 516% increase on H120.
davebowler
15/9/2021
07:42
Half-yearly Report - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/half-yearly-report/202109150700047778L/
speedsgh
20/8/2021
22:12
Net Asset Value(s) - HTTPS://uk.advfn.com/stock-market/london/BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values/85885768 As at the 31 July 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 100.38 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com [31/7/21: 100.38 cents per share] [30/6/21: 99.80 cents per share] [31/5/21: 100.93 cents per share] [30/4/21: 100.27 cents per share] [31/3/21: 99.85 cents per share] [28/2/21: 101.40 cents per share] [31/1/21: 100.84 cents per share] [31/12/20: 100.37 cents per share] [30/11/20: 99.91 cents per share] [31/10/20: 101.13 cents per share] [30/9/20: 101.00 cents per share]
speedsgh
11/8/2021
16:11
M&G has reduced from just under 10% to just under 5%... HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Holdings-in-Company/85799280
speedsgh
22/7/2021
07:43
Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/85638552 As at the 30 June 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 99.80 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com. [30/6/21: 99.80 cents per share] [31/5/21: 100.93 cents per share] [30/4/21: 100.27 cents per share] [31/3/21: 99.85 cents per share] [28/2/21: 101.40 cents per share] [31/1/21: 100.84 cents per share] [31/12/20: 100.37 cents per share] [30/11/20: 99.91 cents per share] [31/10/20: 101.13 cents per share] [30/9/20: 101.00 cents per share]
speedsgh
24/5/2021
18:28
Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/85190709 As at the 30 April 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 100.27 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com. [30/4/21: 100.27 cents per share] [31/3/21: 99.85 cents per share] [28/2/21: 101.40 cents per share] [31/1/21: 100.84 cents per share] [31/12/20: 100.37 cents per share] [30/11/20: 99.91 cents per share] [31/10/20: 101.13 cents per share] [30/9/20: 101.00 cents per share]
speedsgh
23/4/2021
16:50
Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/84903191 As at the 31 March 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 99.85 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com. [28/2/21: 101.40 cents per share] [31/1/21: 100.84 cents per share] [31/12/20: 100.37 cents per share] [30/11/20: 99.91 cents per share] [31/10/20: 101.13 cents per share] [30/9/20: 101.00 cents per share]
speedsgh
31/3/2021
12:03
As always a fascinating drill-down by David Stevenson hTTp://www.adventurousinvestor.com/2519-new-addition-to-prudent-15-biopharma-credit
pob69
26/3/2021
09:22
Stifel; This week BioPharma announced a new investment in UK borrower LumiraDx Investment Limited. The manager expects this “should get them close” to fully covering the BioPharma dividend but there is still c.$98m of cash (or 7% of NAV) still to be deployed. The fund has taken warrants in LumiraDx (details not disclosed) and the interesting aspect is that LumiraDX is exploring an IPO in the US. Finally, while the majority of borrowers historically have been in the US the fund is agnostic to region. However, the pool of potential borrowers is larger in the US and so it’s likely that the US focus will continue. (Analyst: Sachin Saggar)
davebowler
24/3/2021
10:22
Liberum; $150m loan investment Mkt Cap £970m | Prem/(disc) -2.4% | Div yield 7.5% Event Biopharma Credit will invest $150m in a new loan with LumiraDX. The overall size of the facility is $300m with the remaining $150m provided by BioPharma V. The loan is for a term of three years with a fixed interest rate of 8%. The lenders will also receive fees of 4% (2.5% entry and 1.5% exit) and warrants as part of the transaction. LumiraDX is a point of care diagnostic company seeking to bring lab-comparable performance to point of care in minutes. To date, it has developed and launched four diagnostic tests for use with its platform including antigen test and antibody tests for Covid-19. The antigen tests are commercially available in the US and Europe. Existing customers for the antigen test include the NHS and CVS Pharmacy. The company has also started to roll out of a programme to supply Instruments and a significant number of Covid-19 antigen test strips to Africa as part of a collaboration with the Bill & Melinda Gates Foundation. Liberum view The new loan will represent 11% of NAV and will deploy the majority of the outstanding cash balance of $248m. The company received $425m of prepayments in H2 2020, which has led to an element of cash drag on returns in recent months. Prepayment fees and make-whole penalties have compensated for the cash drag and the new investment should add approximately 1 cent per share to recurring earnings (including annualised fees). This would ensure the dividend is broadly fully covered with the likelihood of additional improvements as further capital is deployed.
davebowler
16/3/2021
07:28
Very satisfactory: https://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/annual-financial-report/202103160700093305S/ "No material impact on the credit quality of any loan as a result of the global disruption caused by the Covid-19 pandemic". And they are throwing off dividends which is what we want. (Strictly speaking they are interest distributions and taxable outside an ISA. At 20% I think.)
jonwig
15/3/2021
13:09
"BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, will announce its audited Full Year Results for the period ending 31 December 2020 on Tuesday 16 March 2021."
speedsgh
19/2/2021
16:47
GBP strength not helping?
jonwig
19/2/2021
16:04
Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/84386891 As at the 31 January 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 100.84 cents. The Company's factsheet will be located on the Company's website, hxxp://bpcruk.com.
speedsgh
22/12/2020
11:34
True, but my broker (ii) lets me have a USD account, so I'm not too bothered. And gold is a useful hedge against weaker dollar.
jonwig
22/12/2020
11:28
Currency has been the issue
tiltonboy
22/12/2020
10:19
"...but not a particularly excited one." That's probably a good thing. When it comes to investments, boring suits me down to the ground.
speedsgh
22/12/2020
07:04
speeds - thanks for keeping us up to date with this! I'm still a contented holder, but not a particularly excited one.
jonwig
21/12/2020
21:16
Net Asset Value(s) and Monthly Factsheet - HTTPS://uk.advfn.com/stock-market/london/biopharma-credit-BPCR/share-news/BioPharma-Credit-PLC-Net-Asset-Values-and-Monthly/83953848 As at the 30 November 2020 the unaudited net asset value per Ordinary Share, including current period revenue, was 99.91 cents. The Company's factsheet and investor presentation will be located on the Company's website, hxxp://bpcruk.com.
speedsgh
07/12/2020
13:01
Latest Edison update (issued 24 Nov)... Reinvesting proceeds from loan prepayments - HTTPS://www.edisongroup.com/wp-content/uploads/2020/11/Biopharma-Credit-Reinvesting-proceeds-from-loan-prepayments.pdf
speedsgh
12/11/2020
11:42
Dividend Declaration - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/dividend-declaration/202011120700060560F/ BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the financial period ending 30 September 2020 of $0.0175 per ordinary share and a small special dividend in respect of the financial period ending 31 December 2019 of $0.0001 per ordinary share, payable on 18 December 2020 to ordinary shareholders on the register as at 20 November 2020. The Company has a small revenue reserve remaining for the fiscal year 2019 that it is distributing to ordinary shareholders. The Company has chosen to designate the entire amount of this interim and special dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company. The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share.
speedsgh
09/11/2020
08:21
ADDITIONAL INVESTMENT IN EPIZYME - HTTPS://www.investegate.co.uk/biopharma-credit-plc--bpcr-/rns/additional-investment-in-epizyme/202011090700115786E/ BioPharma Credit PLC (the "Company"), is pleased to announce that it, through its fully owned subsidiary, together with BioPharma Credit Investments V (Master) LP ("BioPharma-V" and jointly with the Company the "Lenders",) has entered into an amended and restated loan agreement with Epizyme, Inc ("Epizyme") dated 3 November 2020. As part of this amendment, the Company will invest an additional US$75 million in the Epizyme loan. Under the original terms of the loan agreement, executed in November 2019, Epizyme borrowed US$70 million in three tranches and the Company previously invested US$35 million with BioPharma-V investing the US$35 million balance. The original US$70 million loan will mature in November 2024 and bears interest at LIBOR plus 7.75 per cent. per annum along with a one-time additional consideration of 2.00 per cent. of the total loan amount. In addition, the facility was expandable by up to US$300 million, subject to mutual agreement between the Lenders and Epizyme after approval of tazemetostat for the treatment of follicular lymphoma. On 23 January 2020, TAZVERIK® was granted accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with epithelioid sarcoma and on 18 June 2020 TAZVERIK received accelerated approval from the FDA for the treatment of patients with relapsed/refractory follicular lymphoma. The amendment increases the aggregate principal amount of the loan to Epizyme to US$220 million through a US$150 million fourth tranche ("Tranche D"), which the parties expect to be drawn in full on 18 November 2020. The Company will invest US$75 million of the US$150 million Tranche D and BioPharma-V will invest the US$75 million balance. Tranche D will have the same fees and coupon as the earlier tranches, will be secured by the same collateral as the earlier tranches, and will mature in November 2026 after eight equal amortization payments beginning in February 2025. As part of the amendment, the amortization terms of the initial US$70 million advanced in the first three tranches were changed from eight equal quarterly payments starting in February 2023 to four equal quarterly payments starting in February 2024. Following the expected Tranche D closing, the facility will remain expandable by up to an additional US$150 million, subject to mutual agreement between the Lenders and Epizyme. "We are delighted to expand our partnership with Epizyme", said Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors, LP. "TAZVERIK is now approved to meet the well-defined unmet patient needs in two very different indications (a solid tumor and a hematologic malignancy), demonstrating its broad therapeutic potential." Further to the 4 November 2019 announcement of the original loan agreement, Royalty Pharma continues to hold approximately 9.1% of the issued share capital of Epizyme and Pablo Legorreta, a principal of Pharmakon and Royalty Pharma, continues to be a member of Epizyme's board of directors.
speedsgh
21/10/2020
19:04
Thanks for posting Looks pleasingly boring
williamcooper104
21/10/2020
18:39
Net Asset Value(s) and Monthly Factsheet - HTTPS://data.fca.org.uk/artefacts/NSM/RNS/3755523.html As at the 30 September 2020 the unaudited net asset value per Ordinary Share, including current period revenue, was 101.00 cents. The Company's factsheet will be located on the Company's website, HTTP://bpcruk.com.
speedsgh
Chat Pages: 3  2  1
ADVFN Advertorial
Your Recent History
LSE
BPCR
Biopharma ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210918 11:57:51